AKT1 and neoplasm: The combined use of a PI3K inhibitor and anti‐Fibulin‐3 antibodies significantly inhibited tumor cell proliferation and growth, suggesting that future studies targeting the PI3K/Akt/mTOR pathway should consider combination therapies [219].